Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts. Presentat...
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and D...
Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel and BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings held earlier today. Pending the expiration of a 30...
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the (JAAD). Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam...
Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a issued on January 16, 2020. Perceptive Advisor...
Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S. Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced a cover...
Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company’s First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against Current Acne Market Leaders REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today annou...
Foamix Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference, taking place December 2-5, 2019 at the Lotte New York Palace Hotel in New York City. Piper Jaffray 31st Annual Healthcare ConferenceDate: T...
Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris. The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%. “W...
Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference Call and Webcast Scheduled for Monday, November 11th at 8:30am Eastern Time REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced financial results for the three and nine months ended September 30, 2019 and provided a corporate update. “The rece...
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses a significant unmet medical need for a serious disease stateFoamix’s sales and marketing infrastructure will provide meaningful leverage to potential launches for product can...
Foamix Announces Issuance of New U.S. Patent for Compositions Combining a Retinoid and a Tetracycline Antibiotic REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders. This newly issued patent, which ex...
Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05 (Studies 04 & 05) in the (JCAD). Studies 04 and 05 were conducted by Foamix to support the New Drug Application submission of AM...
Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11 REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2019, on Monday, November 11, after the market close. Foamix will host a conference call and webcast at ...
Foamix Enters Into Manufacturing and Supply Agreement For AMZEEQ™ and FMX103 Triggers availability of non-dilutive capital under existing credit agreement with Perceptive and OrbiMed REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a long term contract manufacturing and supply agreement with ASM Aerosol-Service (“ASM”) for the Company’s recently approved AMZEEQ™ (minocycline) topical foam, 4% for the treatment of inf...
Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it has entered into a settlement and license agreement with an affiliate of Teva Pharmaceuticals Industries Ltd. (“Teva”) to resolve pending patent litigation involving Finacea® Foam. Details of the settlement agreement are confidential, and the settlement agreement is s...
UPDATE -- Foamix Receives FDA Approval of AMZEEQ™ Topical Minocycline Treatment for Millions of Moderate to Severe Acne Sufferers AMZEEQ is the First-ever FDA Approved Topical Form of Minocycline AMZEEQ Offers Efficacy with Low Systemic Absorption REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%. AMZEEQ, formerly known as FMX101, i...
Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea PDUFA Target Action Date of June 2nd, 2020 REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) f...
Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company, today announced it will present results from nine clinical trials in five posters relating to its investigational topical product candidates FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-to-severe papulopustular rosacea in ad...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.